Roth Capital Thinks Bio Blast’s Stock is Going to Recover

By Austin Angelo

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Bio Blast (NASDAQ: ORPN) yesterday and set a price target of $15. The company’s shares opened today at $1.45, close to its 52-week low of $1.30.

According to, Pantginis is ranked 0 out of 5 stars with an average return of -11.7% and a 34.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Bio Blast has an analyst consensus of Moderate Buy.

The company has a one year high of $7.95 and a one year low of $1.30. Currently, Bio Blast has an average volume of 43.77K.

Bioblast Pharma Ltd. is a clinical development-stage biopharmaceutical company. It focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel.